PEDIATRICS Vol. 83 No. 6 June 1989, pp. 998-1002
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blumberg, D. L.
Right arrow Articles by Bell, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blumberg, D. L.
Right arrow Articles by Bell, J.

Acromegaly in an Infant

Denise L. Blumberg MD1, Charles A. Sklar MD1, Raphael David MD1, Saul Rothenberg PhD1, and Jennifer Bell MD1

1 The Department of Pediatrics, New York University Medical Center, New York, and the Department of Pediatrics, Babies Hospital, Columbia-Presbyterian Medical Center, New York

Serial hormonal studies were carried out in a girl with a growth hormone-secreting pituitary adenoma and hyperprolactinemia diagnosed at 21 months of age, the youngest verified case of acromegaly. The child had progressive macrocephaly, noted at 6 months of age, which preceded the rapid acceleration of linear growth by nearly 1 year. At 21 months of age, the girl's head circumference measured 55 cm (+5.5 SD) and her height was 97.6 cm (+4.4 SD). Preoperative serum growth hormone level was 135 ng/mL, somatomedin C was 1,540 ng/mL (normal for bone age 18 to 97 ng/mL), and prolactin was 370 ng/mL (normal < 20 ng/mL). Following total resection of a large adenoma, immunohistochemical staining of the tumor showed growth hormone but not prolactin. With longitudinal monitoring of the child for 2 years postoperatively, persistently low growth hormone levels were demonstrated and normal growth velocity (6 cm/yr). Peak serum growth hormone levels ranged from 2.8 to 4.1 ng/mL after stimulation tests with insulin, arginine, and L-dopa. Maximum sleep-entrained growth hormone level was 3.4 ng/mL. At the same time, serum somatomedin C levels measured serially were normal (29 to 111 ng/mL), whereas simultaneous prolactin levels were moderately increased (30 to 147 ng/mL). The data support the hypothesis that hyperprolactinemia may have contributed to stimulating somatomedin C and sustaining the normal growth rate in this child.

Key Words: acromegaly • growth hormone • pituitary adenoma • hyperprolactinemia

Submitted on December 31, 1987
Accepted on February 29, 1988




This article has been cited by other articles:


Home page
 CLIN PEDIATRHome page
V. Narayanaswamy, K. R. Rettig, and S. K. Bhowmick
Excessive Growth
Clinical Pediatrics, September 1, 2008; 47(7): 705 - 710.
[Abstract] [PDF]

Home page
 Eur J EndocrinolHome page
M Rix, P Laurberg, A S Hoejberg, and B Brock-Jacobsen
Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl
Eur. J. Endocrinol., August 1, 2005; 153(2): 195 - 201.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. G. Maheshwari, T. R. Prezant, V. Herman-Bonert, H. Shahinian, K. Kovacs, and S. Melmed
Long-Acting Peptidomimergic Control of Gigantism Caused by Pituitary Acidophilic Stem Cell Adenoma
J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3409 - 3416.
[Abstract] [Full Text]

Home page
 CLIN PEDIATRHome page
J. F. Sotos
Overgrowth
Clinical Pediatrics, November 1, 1996; 35(11): 577 - 590.
[PDF]